Casebia, Seattle Children's partner to develop gene-edited Tregs
By Mary Romeo | Sep 29, 2017 | 9:39 PM GMT
Casebia Therapeutics (Cambridge, Mass.) and Seattle Children's Research Institute (Seattle, Wash.) partnered to develop CRISPR-Cas9 (CRISPR-associated protein 9)-edited Tregs to treat and prevent autoimmune diseases.
Read the full 263 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD